4a63
From Proteopedia
Crystal structure of the p73-ASPP2 complex at 2.6A resolution
Structural highlights
Function[P73_HUMAN] Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.[1] [2] [3] [ASPP2_HUMAN] Regulator that plays a central role in regulation of apoptosis and cell growth via its interactions. Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo. Inhibits the ability of APPBP1 to conjugate NEDD8 to CUL1, and thereby decreases APPBP1 ability to induce apoptosis. Impedes cell cycle progression at G2/M. Its apoptosis-stimulating activity is inhibited by its interaction with DDX42.[4] [5] [6] Publication Abstract from PubMedTumor suppressors p53, p63 and p73 comprise a family of stress-responsive transcription factors with distinct functions in development and tumor suppression. Most human cancers lose p53 function, yet all three proteins are capable of inducing apoptosis or cellular senescence. Mechanisms are therefore under investigation to activate p73-dependent apoptosis in p53-deficient cancer cells. Significantly, the DNA-binding domain (DBD) of p73 escapes viral oncoproteins and displays an enhanced thermal stability. To further understand the variant features of p73, we solved the high-resolution crystal structure of the p73 DBD as well as its complex with the ankyrin repeat and SH3 domains of the pro-apoptotic factor ASPP2. The p73 structure exhibits the same conserved architecture as p53 but displays a divergent L2 loop, a known site of protein-protein interaction. The loop in p73 is changed by a two-residue insertion that also induces repacking around the site of the p53 mutational hotspot R175. Importantly, the binding of ASPP2 is preserved by conformational changes in both the ankyrin repeat and SH3 domains. These results further highlight the structural variation that impacts p53 family interactions within the p53 interactome. Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73.,Canning P, von Delft F, Bullock AN J Mol Biol. 2012 Aug 20. pii: S0022-2836(12)00648-1. doi:, 10.1016/j.jmb.2012.08.005. PMID:22917970[7] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||||
Categories: Human | Large Structures | Arrowsmith, C | Bountra, C | Bullock, A N | Canning, P | Cooper, C D.O | Delft, F von | Edwards, A | Keates, T | Krojer, T | Muniz, J | Salah, E | Savitsky, P | Sharpe, T | Vollmar, M | Weigelt, J | Ankyrin | Apoptosis regulatory protein | Cell cycle | Tp53bp2 | Tumour suppressor
